Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

The PD-1/PD-L1 signaling pathway plays a crucial role in cancer immune evasion, and the use of anti-PD-1/PD-L1 antibodies represents a significant milestone in cancer immunotherapy. However, the low response rate observed in unselected patients and the development of therapeutic resistance remain ma...

Full description

Bibliographic Details
Main Authors:	Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu, Ming Yi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Immunology
Subjects:	cancer immunotherapy immunotherapy resistance immune checkpoint inhibitor bispecific antibody TGF-β PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1196970/full

Similar Items

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
by: Mengke Niu, et al.
Published: (2023-08-01)

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
by: Ming Yi, et al.
Published: (2021-02-01)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
by: Ming Yi, et al.
Published: (2022-10-01)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
by: Ming Yi, et al.
Published: (2022-12-01)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
by: Ming Yi, et al.
Published: (2021-09-01)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
by: Ning Shi, et al.
Published: (2022-11-01)

Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
by: Shuping Yin, et al.
Published: (2023-10-01)

Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
by: Junjun Fu, et al.
Published: (2023-03-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
by: Haiping Jiang, et al.
Published: (2021-01-01)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01)

Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies
by: Tianye Li, et al.
Published: (2023-06-01)

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
by: Shuai Hao, et al.
Published: (2022-10-01)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
by: Qingyun Yuan, et al.
Published: (2021-01-01)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
by: Jing Wei, et al.
Published: (2022-10-01)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
by: Brian H. Santich, et al.
Published: (2020-12-01)

Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms
by: Arta M. Monjazeb, et al.
Published: (2021-02-01)

The landscape of bispecific T cell engager in cancer treatment
by: Shujie Zhou, et al.
Published: (2021-05-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
by: Joanie Del Bano, et al.
Published: (2015-12-01)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
by: Yan Yang, et al.
Published: (2021-07-01)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
by: Zheng Tian, et al.
Published: (2021-05-01)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
by: Camila Ordóñez-Reyes, et al.
Published: (2022-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy
by: Irene Tang, et al.
Published: (2023-05-01)

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
by: Po-Lin Huang, et al.
Published: (2023-05-01)

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
by: Zhen-Hua Wu, et al.
Published: (2022-10-01)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021-08-01)

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
by: Xiaohan Guo, et al.
Published: (2023-12-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
by: Xiang Zhou, et al.
Published: (2020-07-01)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
by: Wu Lin, et al.
Published: (2023-10-01)

Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
by: Linwei Li, et al.
Published: (2022-07-01)

A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023
by: Jing Wei, et al.
Published: (2024-01-01)

Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
by: Xin Wang, et al.
Published: (2024-02-01)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021-01-01)

CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways
by: Michael B. Murphy, et al.
Published: (2023-07-01)